Subscribe to receive email updates as new information becomes available.

As early as April 6,2020, the New York Times (NYT) published an article revealing early pandemic statistics that showed the death rate for people with Intellectual or developmental disabilities (IDD) who received residential services in New York State (NYS) was double that for the general population. As difficult as the pandemic has been for all of us, it was clear from the beginning that some were more vulnerable than others.  

By May 2020, we saw the first research on this population, based on the TriNetX data. This study took a deeper dive into the statistics available from NYS.  Although the death rate reported in the NYT was accurate, this research revealed a more complex reality. The case fatality rate for the IDD population was actually comparable to the general population at 5.1%  vs. 5.4%. This suggested that the numbers reported by the NYT were most like related to a higher infection rate for the IDD population, but the study unmasked a more significant issue.  When the statistics were separated into age bands it revealed dramatically worse outcomes for those with IDD at younger ages. The case fatality rate for those over 75 was not higher than their counterparts in the general population, but for adults less than 75 years old, they were almost twice as likely to die from COVID-19, and children 0-17 years old were a whopping 16 times more likely to succumb to COVID-19 than their counterparts in the general population.  


By June 2020, yet another study was published in Disability and Health Journal focused specifically on those with disabilities living in group homes. Once again using the data from New York, the researchers found that the case rate for this population was over four times that of the general population, and their case fatality rate was 15% compared to 7.9% for the general population at that time. The result of those two numbers was an overall mortality rate for this group that was over eight times that of the general population. 

A subsequent study published in the same journal and focused on the California IDD population confirmed the increased risk for those with disabilities living in group settings. Furthermore, this research uncovered a positive correlation between the number of people under one roof and the intensity of services being provided with increasing risk of infection and death from COVID-19. 

As with the disabled populations, there have been several studies showing a differential impact of the pandemic on those with serious mental illness (SMI) that were published in parallel with those cited thus far. An article in Schizophrenia Research leaned heavily on earlier published studies to show that the social distancing in response to COVID-19 would exacerbate symptoms of those with SMI. In particular, they sited literature that showed the increased use of technology along with social isolation increased paranoid delusions and could even trigger psychotic episodes. They further argued that the resulting increase in disorganized thinking and use of street drugs puts the SMI population at increased risk of contracting COVID-19. 

In fact, a subsequent study published in World Psychiatry showed a 7-10 fold increased risk of infection and death in those with mental disorders.


Since a large portion of people with disabilities and SMI have significant co-morbidities, it is challenging to sift out the independent impact of their underlying condition on COVID-19 risk. It seems clear at this point that congregate living, which is prevalent in both of these populations puts them at significantly increased risk, but a Yale study published in September 2020 demonstrated that even after correcting for co-morbidities, people with psychiatric disorders carried a risk of death from COVID-19 that was 1.5 times that of the general population. 

As we continue to refine our approach to executing a vaccination strategy that prioritizes those most at risk, those with disabilities and SMI will require some special consideration. The pandemic creates particular risk and hardship for these populations. Given the data we have on death rates among children with IDD, it will be particularly important to get a vaccine approved for them that is shown to be safe and effective. Beyond that, vaccination programs will need to take into account issues related to these diagnoses that will likely require specialized capacity and capabilities to ensure those most at risk can actually get vaccinated. 

Click here to watch a recent webinar I participated in hosted by Integrated Care Online, in partnership with OPEN MINDS. Register for free access to more first-rate integrated care resources. 

Subscribe to the NextGen® Advisor blog to keep updated with the latest on COVID-19 vaccine efforts and other issues impacting the healthcare community. 

Meet NextGen Ambient Assist, your new AI ally that generates a structured SOAP note in seconds from listening to the natural patient/provider conversation.

Read Now
Dr Lustick

Dr. Martin Lustick

Senior Vice President, NextGen Advisors

Dr. Martin Lustick is a principal and senior vice president with NextGen Healthcare focused on supporting provider organizations in their successful transition from volume to value-based care.

Dr. Lustick earned a BA in History from Cornell and an MD from Columbia. After completing his pediatric residency at Children’s Hospital National Medical Center in Washington, DC, he was in clinical practice for 17 years with Kaiser Permanente of the Mid-Atlantic States. While there, Dr. Lustick held various management and leadership roles, including chief operating officer for the 800-physician medical group. He oversaw development of their hospitalist program, population health capability, and open access delivery model.

Dr. Lustick then served as chief medical officer for ThompsonHealth—a small health system in Canandaigua, NY—where he provided clinical oversight for hospital, SNF, nursing home, IT, and out-patient physician practices.

In 2005, Dr. Lustick assumed the role of SVP & CMO for Excellus BCBS which covers 1.6 million lives comprised of Medicare, Commercial, and Medicaid. In his 13+ year tenure there he led a variety of strategic initiatives, including a patient-centered medical home program which served as the foundation for the plan’s value-based payment strategy. He also led the implementation of an automated authorization program for care management services, development of a clinical quality improvement strategy, and creation of innovative programs in management of low back pain, screening and prevention, opioid addiction, and chronic disease management.

Dr. Lustick has also been very active in the community, serving on boards and committees confronting issues such as: healthcare capacity planning, Health Information Exchange, mental health, substance use disorders, social determinants of health, and childhood obesity.